CARBIOS
26.1.2023 06:46:34 CET | Business Wire | Press release
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005432/en/
(L-R): Martine BRISSET (General Manager Biodegradation Division, Senior Vice President of Carbios Group, and Executive Committee Member) and Delphine DENOIZE (Innovation Programs Funding, Regulation and LCA Director, and Executive Committee Member)
Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies for reinventing the life cycle of plastics and textiles, has strengthened its leadership team with the appointment of Martine BRISSET as Senior Vice President from 1 January 2023. Martine will manage the Biodegradation Division and supervise the Human Resources, Legal, Regulatory, Project Management, Quality Health and Safety departments. Martine BRISSET joins the Group's Executive Committee, as does Delphine DENOIZÉ, who remains Innovation Programs Funding, Regulation and LCA Director with an expanding team.
"Over the past six months, our teams have grown significantly in order to achieve our ambitious targets, and I am very pleased to appoint Martine and Delphine to the Executive Committee," commented Emmanuel LADENT, Chief Executive Officer of Carbios. "Their proven track records, notably within the Carbios Group, strengthen the top management’s expertise and reinforces the diversity of skills needed to succeed in this pivotal year for Carbios’ industrialization and commercialization.”
Martine BRISSET, Senior Vice President of Carbios : “After having supervised the production of thousands of tons of plastic destined for the packaging sector, I am now focused on reducing plastic pollution with our biodegradation and biorecycling solutions. I'm very excited to take on this awesome and exciting challenge, one that makes sense for future generations and for industry."
Martine BRISSET has over 30 years of General Management experience in major international groups within the plastic and paper packaging industry, most notably at Amcor, Huhtamaki, Linpac and Klockner Pentaplast. Since 2021, she has held the position of General Manager of Carbiolice in order to integrate this high-potential subsidiary dedicated to biodegradation within the Carbios Group. In her new position as Senior Vice President of Carbios, her main mission will be to successfully deploy the biodegradation technology, facilitate the international expansion of Carbios' activities, organise the recruitment and training of the Group's employees. With numerous recruitments planned throughout the company in 2023, building Carbios’ attractivity will be a strategic topic.
Delphine DENOIZÉ, Innovation Programs Funding, Regulation and LCA Director : "What drives me is the satisfaction of seeing a project through, from concept to reality. At Carbios, all our projects have a positive impact on the environment, and it’s rising to this challenge that makes me passionate about my work. By becoming a member of the Executive Committee, I will support these projects even more enthusiastically, in terms of their structuring and funding, but also in terms of their regulatory compliance and environmental performance.”
After several years working in innovation within the agricultural industry, it was during her time at Céréales Vallées cluster that Delphine DENOIZÉ discovered and assisted in the creation of Carbios. She joined the company in 2016 and was one of its first twenty employees. Initially in charge of Innovation Funding and Regulation, then Project Management for PET biorecycling, she now oversees all the Group’s projects. Her responsibilities include French and European public funding for innovation, regulatory compliance of processes and products around the world, and assessment of their environmental impact through specific tools such as Life Cycle Assessment.
Executive Committee Members of Carbios Group:
- Emmanuel LADENT, Chief Executive Officer
- Lionel ARRAS, Industrial Development Director
- Mathieu BERTHOUD, Sourcing and Public Affairs Director
- Pascal BRICOUT, Chief Strategy and Financial Officer
- Martine BRISSET, General Manager Biodegradation Division and Senior Vice President of Carbios Group
- Delphine DENOIZÉ, Innovation Programs Funding, Regulation and LCA Director
- Stéphane FERREIRA, Chief Business Officer
- Lise LUCCHESI, Intellectual Property Director
- Prof. Alain MARTY, Chief Scientific Officer
Visit Carbios’ website for biographies of each individual member: https://www.carbios.com/en/governance/
About Carbios
Established in 2011 by Truffle Capital, Carbios is a green biotech company, developing biological and innovative processes. Through its unique approach of combining enzymes and plastics, Carbios aims to address new consumer expectations and the challenges of a broad ecological transition by taking up a major challenge of our time: plastic and textile pollution. Carbios deconstructs any type of PET (the dominant polymer in bottles, trays, textiles made of polyester) into its basic components which can then be reused to produce new PET plastics with equivalent quality to virgin ones. This PET innovation, the first of its kind in the world, was recently recognized in a scientific paper published in front cover of the prestigious journal Nature. Carbios successfully started up its demonstration plant in Clermont-Ferrand in 2021. It has now taken another key step towards the industrialization of its process with the construction of a first-of-a-kind unit in partnership with Indorama Ventures.
In 2017, Carbios and L’Oréal co-founded a consortium to contribute to the industrialization of its proprietary recycling technology. Committed to developing innovative solutions for sustainable development, Nestlé Waters, PepsiCo and Suntory Beverage & Food Europe joined this consortium in April 2019. In 2022, Carbios signed an agreement with On, Patagonia, PUMA, and Salomon, to develop solutions promoting the recyclability and circularity of their products.
The Company has also developed an enzymatic biodegradation technology for PLA-based (a bio sourced polymer) single-use plastics. This technology can create a new generation of plastics that are 100% compostable at ambient temperatures, even in domestic conditions, integrating enzymes at the heart of the plastic product.
For more information, please visit carbios.com / Twitter: Carbios / LinkedIn: Carbios / Instagram: insidecarbios
Carbios (ISIN FR0011648716/ALCRB) is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.
Translation is for information purposes only.
In case of discrepancy between the French and the English version of this press release, the French version shall prevail
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
